- Home
- XYF vs MOLN Comparison
XYF vs MOLN Comparison
Compare XYF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | XYF | MOLN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.1M | 147.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XYF | MOLN |
|---|---|---|
| Price | $4.83 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 48.4K | 1.9K |
| Earning Date | 11-19-2026 | 10-29-2026 |
| Dividend Yield | ★ 11.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $3.52 |
| 52 Week High | $13.16 | $5.36 |
Technical Indicators
Market Signals| Indicator | XYF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 39.53 |
| Support Level | $4.62 | N/A |
| Resistance Level | $5.15 | $4.21 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 21.25 | 15.12 |
Price Performance
Historical ComparisonAbout XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.